Ultrasonographic Findings of Medullary Thyroid Carcinoma: a Comparison with Papillary Thyroid Carcinoma

Sung-Hun Kim, MD1
Bum-Soo Kim, MD1
So-Lyung Jung, MD1
Jung-Whee Lee, MD1
Po-Sung Yang, MD1
Bong-Joo Kang, MD1
Hyun-Wook Lim, MD1
Jee-Young Kim, MD1
In-Yong Whang, MD1
Heuk-Sang Kwon, MD2
Chan-Kwon Jung, MD3

Objective: This study was designed to evaluate the ultrasonographic (US) findings of medullary thyroid carcinoma (MTC) as compared to findings for papillary thyroid carcinoma (PTC).

Materials and Methods: The study included 21 cases of MTC that were surgically diagnosed between 2002 and 2007 and 114 cases of PTC that were diagnosed in 2007. Two radiologists reached a consensus in the evaluation of the US findings. The US findings were classified as recommended by the Thyroid Study Group of the Korean Society of Neuroradiology and Head and Neck Radiology (KSNHNR) and each nodule was identified as suspicious malignant, indeterminate or probably benign. The findings of medullary and papillary carcinomas were compared with use of the chi-squared test.

Results: The common US findings for MTCs were solid internal content (91%), an ovoid to round shape (57%), marked hypoechogenicity (52%) and calcifications (52%). Among the 21 cases of MTC nodules, 17 (81%) were classified as suspicious malignant nodules. The mean size (longest diameter) of MTC nodules was 19 ± 13.9 mm and the mean size (longest diameter) of PTC nodules was 11 ± 7.4 mm; this difference was statistically significant (p < 0.05). An ovoid to round shape was more prevalent for MTC lesions than for PTC lesions (p < 0.05).

Conclusion: The US criteria for suspicious malignant nodules as recommended by the Thyroid Study Group of the KSNHNR correspond to most MTC cases. The US findings for MTC are not greatly different from PTC except for the prevalence of an ovoid to round shape.

Medullary thyroid carcinoma (MTC) accounts for 3.5–10% of all thyroid malignancies (1) and lesions are derived from the parafollicular C-cells that produce calcitonin (2). The serum calcitonin level is known as a sensitive and specific marker for MTC. However, not all MTCs secrete calcitonin (3), and hypercalcitoninemia is known to be associated with chronic thyroiditis and C-cell hyperplasia in addition to MTC (4). Routine measurement of plasma calcitonin levels in patients who have thyroid nodules has not been widely adopted (5). Therefore, knowledge of the imaging characteristics of MTC is as important as the serum calcitonin level for the early detection and precise diagnosis of MTC. Numerous studies that have evaluated the ultrasonographic (US) findings of malignant thyroid nodules have been conducted (6–11). Most studies have focused on papillary thyroid carcinomas (PTCs), which account for more than 70% of all malignant nodules (10–13). Studies that have evaluated the US findings of MTC are rare (14, 15). In this study, we have evaluated the US findings of MTC as compared with the US findings of PTC.
MATERIALS AND METHODS

Patients
This study included 21 cases (18 patients; 15 females and 3 males; age range, 26–70 years; mean patient age, 55 years) that were surgically diagnosed as an MTC between 2002 and 2007. Three patients had bilateral MTCs (16.7%). Sixteen patients had a sporadic MTC, and two patients had type IIa multiple endocrine neoplasia (MEN). One MEN type IIa patient had bilateral adrenal pheochromocytomas and another patient had bilateral adrenal hyperplasia. The basal calcitonin level of the 15 MTC patients was measured prior to surgery and in 14 patients the serum calcitonin level was elevated (range, 24.7–355 pg/mL; median level, 171.4 pg/mL); the normal range for an immunoradiometric assay is 10 pg/mL. As the MTC US findings of MTC were to be compared with the PTC US findings, a control group of 114 PTC cases that were surgically diagnosed during 2007 (99 patients; 85 females and 14 males; age range, 27–76 years; mean age, 50.4 years) was established. Fifteen patients had bilateral PTCs (13.2%).

US Imaging
High resolution US examinations of the thyroid were performed with a HDI 3000 scanner (Advanced Technology Laboratories, Philips Medical Systems, Bothell, WA) and a HDI 5000 scanner (Philips Medical Systems) equipped with a 5–10 MHz linear array transducer. Examinations were performed by radiology residents and by the radiologists in charge of thyroid imaging (with one to 16 years of experience).

Imaging Analysis and Statistical Analysis
The US images were analyzed retrospectively in a blind review by two radiologists in charge of thyroid imaging with two and 16 years of experience, respectively. By summarization of the classifications of US findings (size, internal content, shape, margin, echogenicity and calcifications) as recommended by the Thyroid Study Group of the Korean Society of Neuroradiology and Head and Neck Radiology (KSNHNR), each nodule was identified as suspicious malignant nodule.

Table 1. Comparison of Ultrasonographic Findings of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma

| Ultrasonographic Findings | Medullary Carcinoma (n = 21) | Papillary Carcinoma (n = 114) | P value |
|---------------------------|-----------------------------|-------------------------------|---------|
| Lesion size               | 19 ± 13.9 mm                | 11 ± 7.5 mm                   | < 0.05  |
| Internal content          |                             |                               |         |
| solid                     | 19 (90.5%)                  | 110 (96.5%)                   | 0.219   |
| predominantly solid       | 2 (9.5%)                    | 4 (3.5%)                      |         |
| predominantly cystic      | 0 (0%)                      | 0 (0%)                        |         |
| cystic                    | 0 (0%)                      | 0 (0%)                        |         |
| Shape                     |                             |                               |         |
| ovoid to round            | 12 (57.1%)                  | 29 (25.4%)                    | < 0.05  |
| *taller than wide         | 4 (19.0%)                   | 48 (42.1%)                    |         |
| irregular                 | 5 (23.8%)                   | 37 (32.5%)                    |         |
| Margin                    |                             |                               |         |
| smooth                    | 4 (19.0%)                   | 22 (19.3%)                    | 0.964   |
| *spiculated               | 9 (42.8%)                   | 44 (38.6%)                    |         |
| ill-defined               | 8 (38.1%)                   | 48 (42.1%)                    |         |
| Echogenicity              |                             |                               |         |
| *markedly hypoechoic      | 11 (52.4%)                  | 65 (57.0%)                    | 0.894   |
| hypoechoic                | 9 (42.9%)                   | 42 (36.8%)                    |         |
| isoechoic                 | 1 (4.8%)                    | 5 (4.4%)                      |         |
| hyperechoic               | 0 (0%)                      | 2 (1.8%)                      |         |
| Califications             |                             |                               |         |
| no calcifications         | 10 (47.6%)                  | 37 (32.5%)                    | 0.348   |
| *microcalcifications      | 6 (28.6%)                   | 53 (46.5%)                    |         |
| *macrocalcifications      | 5 (23.8%)                   | 21 (18.4%)                    |         |
| rim calcifications        | 0 (0%)                      | 3 (2.6%)                      |         |

Note — *If nodule had any one of these features on ultrasonography, it was classified as suspicious malignant nodule.
suspicious malignant, indeterminate or probably benign (6). An analysis for distant or regional metastases, including lymph node metastases, was not performed in this study. With respect to the size of the nodules, the longest diameter measured by US was selected and was expressed as the mean ± standard deviation.

The internal contents of the nodules were defined as solid (a solid component more than 90%), predominantly solid (a solid component more than 50% but less than 90%), predominantly cystic (a solid component more than 10% but less than 50%) and cystic (solid component less than 10%). The shape of nodules was defined as ovoid to round, taller than wide (the anteroposterior dimension was longer than the transverse diameter), or irregular (neither round to oval nor taller than wide). The border characteristics were defined as smooth, spiculated or ill defined. Echogenicity was defined as markedly hypoechoic (less than the strap muscle echogenicity), hypoechoic (less than the thyroid echogenicity), isoechoic (equal to the thyroid echogenicity) or hyperechoic (greater than the thyroid echogenicity). Calcifications were defined as microcalcifications (tiny punctate hyperechogenicities either with or without acoustic shadowings of less than 1 mm in diameter), macrocalcifications (larger than 1 mm in diameter) or rim calcifications. Malignant sonographic characteristics were defined as a shape that was taller than wide, with a spiculated border, marked hypoechoogenicity and micro calcifications or macrocalcifications. If a nodule had any one of these features that are suggestive of a malignancy, the lesion was classified as a suspicious malignant nodule. A probably benign nodule was classified as either completely cystic or predominantly cystic with a comet tail artifact. An indeterminate nodule was defined as a nodule that was not suspicious for malignancy or showed probably benign findings. The findings of medullary and papillary carcinomas were compared with use of the chi-squared test. A p-value of less than 0.05 was defined as statistically significant.

RESULTS

The US findings of the MTCs and PTCs are summarized in the Table 1. For the MTCs, a solid internal content (19 of 21, 90.5%), ovoid to round shape (12 of 21, 57.1%), marked hypoechogenicity (11 of 21, 52.4%), microcalcifications or macrocalcifications (11 of 21, 52.4%) and a spiculated or ill-defined margin (17 of 21, 80.9%) were the prevailing findings seen on US. For 21 MTCs, 17 (81%) were categorized as suspicious malignant nodules, and four (19%) were categorized as indeterminate nodules (Figs. 1, 2). None of the lesions were categorized as probably benign nodules. For the PTCs, the prevailing findings as seen on US were a solid internal content (110 of 114, 96.5%), taller than wide shape (48 of 114, 48%), irregular border (48 of 114, 42.1%), marked hypoechogenicity (65 of 114, 57.0%) and microcalcifications or macrocalcifications (74 of 114, 64.9%). For 114 PTCs, 107 (94%) were categorized as suspicious malignant nodules and seven (6%) were categorized as indeterminate nodules (Fig. 3).

The mean size (19 ± 13.9 mm vs. 11 ± 7.5 mm) and ovoid to round shape (57.1% vs. 25.4%) were statistically different between the MTCs and PTCs. However, the
internal content, margin, echogenicity and calcifications were not statistically significantly different between the two types of nodules. Most of the MTC and PTC nodules were classified as suspicious malignant; however, the frequency of an indeterminate nodule was higher for the MTCs than for the PTCs.

DISCUSSION

Eighty to ninety percent of MTCs have been considered as sporadic and the rest have been classified as hereditary (1). The familial form of the tumor usually occurs as a component of type IIa MEN (Sipple syndrome), which is characterized by the combination of an MTC, adrenal pheochromocytoma and hyperplasia of the parathyroid glands. MEN type IIb is a highly unusual form of the MEN II syndrome and consists of elements of type IIa and additional features of marfanoid habitus, mucosal neuromas and intestinal ganglioneuromatosis. In the present study, 16 patients were categorized as having the sporadic form and two patients were categorized as having MEN type IIa.

Fine needle aspiration (FNA) of thyroid nodules has become one of the most useful, safe and accurate methods used to diagnose thyroid pathology. US findings are important to evaluate and prioritize nodules during FNA. US findings have been reported to be of great help to distinguish malignant from benign nodules (6–11, 13). The US findings that have been reported for malignant thyroid nodules have included completely solid or predominantly solid nodules, hypoechogenicity as compared with the strap muscles, an irregular margin, intranodular microcalcifications, a taller than wide orientation and increased intranodular vascularity. Moon et al. (6) reported in a multicenter retrospective study the US findings of benign and malignant thyroid nodules (6). The Thyroid Study Group of the KSNHNR organized this study, which was performed on patients from nine university hospitals and large general hospitals in the Republic of Korea. The findings suggested malignancy in nodules with a taller than wide shape, spiculated margin, marked hypoechogenicity, and intranodular microcalcifications (including microcalcifications or macrocalcifications). The findings of the study demonstrated a high sensitivity (93.8%) and a high negative predictive value (95.9%). In most cases, the malignant nodules that were included in the Moon et al. (6) study and similar studies were PTCs, and most of the PTCs correlated with the US findings of malignant thyroid nodules (10–13). However, studies on the US findings of MTC are not common (14, 15). Gorman et al. (14) reported on the high-resolution US findings of MTC in 1987. All of the tumors (six lesions in six patients) appeared hypoechogenic and were relatively well defined. Bright echogenic foci were reported in five patients (83.3%), and this finding was supported by the histological finding of focal deposits of calcium surrounded by amyloid. In 2002, Saller et al. (15) reported the US findings of 19 MTC cases. All of the cases showed hypoechogenicity. The present study evaluated 21 MTC cases, a higher number than in previous studies. Most MTC nodules (95.3%) were markedly hypoechogenic (52%) or hypoechogenic (42.9%), and our findings are similar to the findings of the above two studies (14, 15). In the current study, intranodular calcifications were observed in 52% of the MTC patients. As compared to the results of the Gorman et al. (83.3%) and Saller et al. (95%) studies, we found a low calcification rate.

Studies comparing the US findings of MTC with PTC have not been previously conducted and we compared and analyzed the US findings of 21 MTC cases and 114 PTC cases. The mean size of MTC nodules was larger than that of PTC nodules (19 ± 13.9 mm vs. 11 ± 7.5 mm, p < 0.05). In a comparison of the US findings, 57% of MTCs and 25% of PTCs exhibited an ovoid to round shape, which was significantly higher for the MTC nodules (p < 0.05). However, internal content, margin, echogenicity and frequency of calcifications were not significantly different between MTCs and PTCs. Most MTC (80.9%) and PTC (93.9%) nodules were classified as suspicious malignant.
nODULES. However, in a comparison of MTCs with PTCs, suspicious malignant nodules were found less frequently and indeterminate nodules were found more frequently in MTC than in PTC. This finding can be attributed to a significantly higher frequency of ovoid to round shape in MTC, which is not a suspicious malignant feature. Both MTCs and PTCs have been associated with calcifications more than other thyroid malignancies. The association of an MTC with amyloid deposition pathologically distinguishes this type of tumor from other thyroid malignancies (16). A myloid deposits may be associated with reactive fibrosis and calcified deposits that give rise to characteristic-ly dense, irregular foci throughout the tumor mass. This observation is in contrast with the faint homogeneous calcifications seen in other thyroid tumors (1). Dense and irregular calcifications are known as a characteristic finding of MTC; these macrocalcifications were seen in five MTC nodules (23.8%) and in 21 PTC nodules (18.4%). Saller et al. (15) defined calcifications longer than 2 mm as macrocalcifications, and reported the presence of macrocalcifications in 53% of MTC patients in their study; this frequency was higher than in our study. Chan et al. (11) found that among 55 PTC cases, 11% were associated with macrocalcifications; this frequency was similar to the frequency seen in the present study. The presence of microcalcifications is a known characteristic finding of PTC and microcalcifications have been reported in 29–59% of all thyroid carcinomas (17). In our study, microcalcifications were found in 29% of MTCs and 47% of PTCs. A according to the findings in the study by Chan et al. (11), 42% of PTCs were associated with microcalcifications, a finding that is similar to our results. Saller et al. (15) reported that microcalcifications less than 2 mm in length were seen in 42% of MTCs.

Serum calcitonin levels rise in MTC patients as MTCs are derived from parafollicular C-cells that produce calcitonin (2). However, not all MTCs secrete calcitonin and in particular, more advanced tumors may dedifferentiate with a subsequent decrease in calcitonin production (3). In the present study, the basal calcitonin level was elevated in 14 patients and was within the normal range in one patient. The patient with a normal calcitonin level had a huge, 7 cm thyroid mass with an extensive necrotic lymph node metasta-sis and perithyroidal soft tissue invasion. The pathological result was a poorly differentiated pattern of MTC.

In conclusion, the common US features of MTC are a solid internal content, an ovoid to round shape, marked hypoechochogenicity and calcifications. Most MTCs showed US findings of suspicious malignant nodules, as reported by the Thyroid Study Group of the KSNHNR. The US findings were not greatly different between MTCs and PTCs, except that the ovoid to round shape was more abundant in MTCs.

References
1. McCook TA, Putman CE, Dale JK, Wells SA. Medullary carcinoma of the thyroid: radiographic features of a unique tumor. AJR Am J Roentgenol 1982;139:149-155
2. Melvin KE, Tashjian AH Jr. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl Acad Sci USA 1968;59:1216-1222
3. Busnardo B, Girelli ME, Simioni N, Namamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984;53:278-285
4. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezi C, et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest 2006;29:427-437
5. You YN, Lakhani V, Wells SA Jr, Moley JF. Medullary thyroid cancer. Surg Oncol Clin N Am 2006;15:639-660
6. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, et al. Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study. Radiology 2008;247:762-770
7. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794-800
8. Iannuccilli JD, Cronan JJ, Monchik JM. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. J Ultrasound Med 2004;23:1455-1464
9. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 2002;178:687-691
10. Shimura H, Haraguchi K, Hiejima Y, Fujunari N, Fujimoto Y, Katagiri M, et al. Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: a multicenter study. Thyroid 2005;15:251-258
11. Chan BK, Dessert TS, McDougal IR, Weigel R, Jeffrey RB Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003;22:1083-1090
12. Pellitteri PK, McCaffrey TV. Tumor and tumor-like lesion in thyroid endocrine surgery of the head and neck, 1st ed. Pennsylvania: Singular publish group, 2002:21-47
13. J je SK, Jung SL, Kim BS, Lee YS. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. Korean J Radiol 2007;8:192-197
14. Gorman B, Charboneau JW, James EM, Reading CC, Wold LE, Grant CS, et al. Medullary thyroid carcinoma: role of high-resolution US. Radiology 1987;162:147-150
15. Saller B, Moeller L, Gorges R, Janssen OE, Mann K. Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 2002;110:403-407
16. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1966;19:114-118
17. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US features of thyroid malignancy: pearls and pitfalls. Radiographics 2007;27:847-860